Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002871 (
anemia
)
52,094
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The Ref1 and Lv1 postentry restrictions in human and monkey cells have been analyzed for lentiviruses in the primate and ungulate groups, but no data exist for the third (feline) group. We compared feline immunodeficiency virus (FIV) to other restricted (human immunodeficiency virus type 1 [HIV-1], equine infectious
anemia
virus [EIAV]) and unrestricted (NB-tropic murine leukemia virus [NB-MLV]) retroviruses across wide ranges of viral inputs in cells from multiple primate and nonprimate species. We also characterized restrictions conferred to permissive feline and canine cells engineered to express rhesus and human
TRIM5alpha
proteins and performed RNA interference (RNAi) against endogenous
TRIM5alpha
. We find that expression of rhesus or human
TRIM5alpha
proteins in feline cells restricts FIV, impairing pseudotyped vector transduction and viral replication, but rhesus
TRIM5alpha
is more restricting than human
TRIM5alpha
. Notably, however, canine cells did not support restriction by human
TRIM5alpha
and supported minimal restriction by rhesus
TRIM5alpha
, suggesting that these proteins may not function autonomously or that a canine factor interferes. Stable RNAi knockdown of endogenous rhesus
TRIM5alpha
resulted in marked increases in FIV and HIV-1 infectivities while having no effect on NB-MLV. A panel of nonprimate cell lines varied widely in susceptibility to lentiviral vector transduction, but normalized FIV and HIV-1 vectors varied concordantly. In contrast, in human and monkey cells, relative restriction of FIV compared to HIV-1 varied from none to substantial, with the greatest relative infectivity deficit for FIV vectors observed in human T-cell lines. Endogenous and introduced
TRIM5alpha
restrictions of FIV could be titrated by coinfections with FIV, HIV-1, or EIAV virus-like particles. Arsenic trioxide had complex and
TRIM5alpha
-independent enhancing effects on lentiviral but not NB-MLV infection. Implications for human gene therapy are discussed.
...
PMID:Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins. 1630 89
The restriction factors,
TRIM5alpha
in most primates and TRIMCyp in owl monkeys, block infection of various retroviruses soon after virus entry into the host cell. Rhesus monkey
TRIM5alpha
(
TRIM5alpha
rh) inhibits human immunodeficiency virus (HIV-1) and feline immunodeficiency virus (FIV) more potently than human
TRIM5alpha
(
TRIM5alpha
hu). TRIMCyp restricts infection of HIV-1, simian immunodeficiency virus of African green monkeys (SIV agm) and FIV. Early after infection, TRIMCyp, like
TRIM5alpha
rh and
TRIM5alpha
hu, decreased the amount of particulate viral capsid in the cytosol of infected cells. The requirements for the TRIMCyp and
TRIM5alpha
domains in restricting different retroviruses were investigated. Potent restriction of FIV by TRIMCyp occurred in the complete absence of RING and B-box 2 domains; by contrast, efficient FIV restriction by
TRIM5alpha
rh required these domains. Variable region 1 of the
TRIM5alpha
rh B30.2 domain contributed to the potency of HIV-1, FIV and equine infectious
anemia
virus restriction. Thus, although differences exist in the requirements of TRIMCyp and
TRIM5alpha
for RING/B-box 2 domains, both restriction factors exhibit mechanistic similarities.
...
PMID:Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. 1792 96
The rhesus monkey intrinsic immunity factor
TRIM5alpha
(rh) recognizes incoming capsids from a variety of retroviruses, including human immunodeficiency virus type 1 (HIV-1) and equine infectious
anemia
virus (EIAV), and inhibits the accumulation of viral reverse transcripts. However, direct interactions between restricting
TRIM5alpha
proteins and retroviral capsids have not previously been demonstrated using pure recombinant proteins. To facilitate structural and mechanistic studies of retroviral restriction, we have developed methods for expressing and purifying an active chimeric
TRIM5alpha
(rh) protein containing the RING domain from the related human TRIM21 protein. This recombinant TRIM5-21R protein was expressed in SF-21 insect cells and purified through three chromatographic steps. Two distinct TRIM5-21R species were purified and shown to correspond to monomers and dimers, as analyzed by analytical ultracentrifugation. Chemically cross-linked recombinant TRIM5-21R dimers and mammalian-expressed TRIM5-21R and
TRIM5alpha
proteins exhibited similar sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobilities, indicating that mammalian
TRIM5alpha
proteins are predominantly dimeric. Purified TRIM5-21R had ubiquitin ligase activity and could autoubquitylate with different E2 ubiquitin conjugating enzymes in vitro. TRIM5-21R bound directly to synthetic capsids composed of recombinant HIV-1 CA-NC proteins and to authentic EIAV core particles. HIV-1 CA-NC assemblies bound dimeric TRIM5-21R better than either monomeric TRIM5-21R or TRIM5-21R constructs that lacked the SPRY domain or its V1 loop. Thus, our studies indicate that
TRIM5alpha
proteins are dimeric ubiquitin E3 ligases that recognize retroviral capsids through direct interactions mediated by the SPRY domain and demonstrate that these activities can be recapitulated in vitro using pure recombinant proteins.
...
PMID:Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. 1879 73
TRIM5alpha
is a retrovirus restriction factor in the host cell cytoplasm that blocks infection before provirus establishment. Restriction activity requires capsid (CA)-specific recognition by the PRYSPRY domain of
TRIM5alpha
. To better understand the restriction mechanism, nine charge-cluster-to-triple-alanine mutants in the
TRIM5alpha
PRYSPRY domain were assessed for CA-specific restriction activity. Five mutants distributed along the
TRIM5alpha
PRYSPRY primary sequence disrupted restriction activity against N-tropic murine leukemia virus and equine infectious
anemia
virus. Modeling of the
TRIM5alpha
PRYSPRY domain based on the crystal structures of PRYSPRY-19q13.4.1, GUSTAVUS, and TRIM21 identified a surface patch where disruptive mutants clustered. All mutants in this patch retained CA-binding activity, a reticular distribution in the cytoplasm, and steady-state protein levels comparable to those of the wild type. Residues in the essential patch are conserved in
TRIM5alpha
orthologues and in closely related paralogues. The same surface patch in the TRIM18 and TRIM20 PRYSPRY domains is the site of mutants causing Opitz syndrome and familial Mediterranean fever. These results indicate that, in addition to CA-specific binding, the PRYSPRY domain possesses a second function, possibly binding of a cofactor, that is essential for retroviral restriction activity by
TRIM5alpha
.
...
PMID:An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding. 1915 41